Clinical Trial Update: Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation trial evaluating the safety, tolerability, and efficacy of EA-2353 in subjects with Retinitis Pigmentosa was terminated (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa
• Retinitis Pigmentosa Syndrome

Drugs mentioned

• EA-2353 (EA-2353)

Snippet

Sponsor: Endogena Therapeutics, Inc | Conditions: Retinitis Pigmentosa, Retinitis Pigmentosa Syndrome | Phase 1, Phase 2 | Status: TERMINATED